Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus
Authors
Keywords
-
Journal
Open Forum Infectious Diseases
Volume 8, Issue 12, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-12-08
DOI
10.1093/ofid/ofab537
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV
- (2021) Bernard Surial et al. ANNALS OF INTERNAL MEDICINE
- Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials
- (2021) Kristine M Erlandson et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir-associated hyperglycaemia in patients with HIV
- (2020) Mohammed Lamorde et al. Lancet HIV
- The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes
- (2020) Jennifer Gorwood et al. CLINICAL INFECTIOUS DISEASES
- Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators
- (2020) Steven K Grinspoon et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
- (2020) Alexandra Calmy et al. Lancet HIV
- Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
- (2020) Cecile D. Lahiri et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Using propensity scores to estimate effects of treatment initiation decisions: State of the science
- (2020) Michael Webster‐Clark et al. STATISTICS IN MEDICINE
- Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era
- (2020) Stephanie A. Ruderman et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
- (2019) Steven K. Grinspoon et al. AMERICAN HEART JOURNAL
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid changes due to tenofovir alafenamide are reversible by switching back to tenofovir disoproxil fumarate
- (2019) Ana Milinkovic et al. AIDS
- Weight Gain Associated with Integrase Stand Transfer Inhibitor Use in Women
- (2019) Anne Marie Kerchberger et al. CLINICAL INFECTIOUS DISEASES
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
- (2018) Mario Gomez et al. INFECTION
- Trends in obesity and diabetes across Africa from 1980 to 2014: an analysis of pooled population-based studies
- (2017) et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Weight Gain: A Possible Side Effect of All Antiretrovirals
- (2017) Lucia Taramasso et al. Open Forum Infectious Diseases
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
- (2015) Peter C. Austin et al. STATISTICS IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started